Table 1 Characteristic of selected studies in the meta-analysis
From: Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis
Author | Year/country | Gender | Tumor stage | Antibody | Dilution | Follow up | Quality |
|---|---|---|---|---|---|---|---|
(M/F) | source | Score | |||||
Wang et al | 2014/China | 25/27 | TNM | Maixin | NA | 40 mo | 8 |
Yang et al | 2010/China | 33/25 | Duke | Santa Cruz | 1:50 | 5 yrs | 8 |
Pap et al | 2009/Romania | 71/46 | Duke | Fremont | 1:50 | NA | 8 |
Hashimoto et al | 2008/USA | 79/52 | TNM | Serotec | 1: 100 | 38 mo | 9 |
Qi et al | 2008/China | 33/19 | Duke | Maixin | NA | NA | 7 |
Feng et al | 2007/China | 20/11 | TNM | Zhongshan | 1:75 | NA | 8 |
Lundin et al | 2005/Finland | 118/119 | Duke | Serotec | 1:100 | 116 mo | 9 |
Zhou et al | 2005/China | 33/19 | Duke | Zhongshan | NA | NA | 7 |
Zuo et al | 2004/China | 29/22 | Duke | Zhongshan | NA | NA | 7 |
Fujiya et al | 2001/Japan | 65/40 | TNM | Santa Cruz | 1:50 | 10 yrs | 9 |